<DOC>
	<DOCNO>NCT02704104</DOCNO>
	<brief_summary>This study design monitor patient safety excision skin lesion subsequent application AC5 topical hemostatic agent ass performance AC5 control bleed skin wound .</brief_summary>
	<brief_title>Safety Performance Evaluation Topical Hemostatic Device ( AC5™ ) Following Excision Skin Lesions</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Men woman age 18 85 . Voluntary write informed consent , give performance clinical investigationrelated procedure part standard medical care , understand consent may withdraw time without prejudice future medical care . Scheduled excision 2 ( two ) skin lesion trunk upper limb ( defined lie level inferior border patient 's mandible ) . If subject currently prescribe antiplatelet therapy , must one follow therapy level per hospital protocol : Antiplatelet monotherapy one follow agent : Aspirin Clopidogrel ( thienopyridineclass antiplatelet agent ) Ticagrelor Dipyridamole Female subject must meet least one follow additional criterion : Surgically sterile bilateral tubal ligation hysterectomy . Postmenopausal least one year . If childbearing potential , practice acceptable method birth control duration clinical investigation judge Investigator , condom , foam , jelly , diaphragm , intrauterine device abstinence . Subjects willing undergo preand postclinical investigation blood urine collection , physical exam laboratory investigation . Active infection demonstrate temperature &gt; 37.5 C clinical feature active infection . Wound expect expose bone tendon . Wound expect require topical antibiotic . Know contraindication reaction Tegaderm use . Presence malignancy clinical expectation malignancy base examination . Known immunosuppression take immunosuppressive agent include systemic steroid . Plan adjunctive flap graft procedure obtain closure wound ( ) subject study . History severe comorbidity expect patient survival ≤ 6 month . Pregnancy lactation Intake investigational drug within 28 day prior enrollment . Currently take oral anticoagulant History concurrent condition , Investigator 's opinion , would jeopardize safety subject compliance protocol . History clinically significant , active disease ( within 12 month prior enrollment ) pulmonary , gastrointestinal , neurological , genitourinary , renal , haematological system , opinion Principal Investigator , may confound result trial pose additional risk subject follow administration AC5 . History clinically significant cardiac disorder , define : acute coronary syndrome , congestive heart failure ( NYHA class III/IV ) , diagnosis unstable angina pectoris , cerebral stroke myocardial infarction within last 12 month plan coronary carotid revascularisation procedure anytime 30 Day followup . History severe uncontrolled treated untreated hypertension ( systolic blood pressure ≥180 mmHg diastolic blood pressure ≥100 mmHg ) . Likely inability comply protocol cooperate fully investigator site personnel . Presence significant cognitive impairment ( Mini Mental Status Examination &lt; 22 ) mental incapacity . Unwillingness language barrier preclude adequate understanding trial procedure cooperation trial site personnel . Known suspect active abuse alcohol , narcotic nonprescription drug . Other plan surgical procedure within 30 day prior 30 day postindex procedure . Prior enrollment AC5 clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>